Newcastle University’s research has shown that children with the most common form of brain cancer could benefit from reduced diagnostic wait times, thanks to ... Sep 02
The designation entitles Moleculin to receive a transferrable Priority Review Voucher (PRV) upon New Drug Approval (NDA)... Dec 03
The company is encouraged by the patient's strong response to Silmitasertib and will make every effort to provide the drug to critically ill COVID-... Sep 12
-Advertisements-